TOP > 外国特許検索 > Cytidine deaminase

Cytidine deaminase UPDATE

外国特許コード F080001882
整理番号 F080001882
掲載日 2008年6月27日
出願国 アメリカ合衆国
出願番号 48452906
公報番号 20060246568
公報番号 7314621
出願日 平成18年7月11日(2006.7.11)
公報発行日 平成18年11月2日(2006.11.2)
公報発行日 平成20年1月1日(2008.1.1)
国際出願番号 JP2000001918
国際公開番号 WO2000058480
国際出願日 平成12年3月28日(2000.3.28)
国際公開日 平成12年10月5日(2000.10.5)
優先権データ
  • 特願1999-087192 (1999.3.29) JP
  • 特願1999-178999 (1999.6.24) JP
  • 特願1999-371382 (1999.12.27) JP
  • 2000WO-JP01918 (2000.3.28) WO
  • 2001US-09966880 (2001.9.28) US
  • 2004US-10884878 (2004.7.2) US
発明の名称 (英語) Cytidine deaminase UPDATE
発明の概要(英語) (US7314621)
Antibodies that specifically bind to AID (Activation-Induced cytidine Deaminase) proteins, compositions comprising said antibodies, and cells producing said antibodies, are described.
The AID proteins are structurally related to APOBEC-1,l an RNA editing enzyme, and have a cytidine deaminase activity similar to APOBEC-1.
The AID genes were found by preparing cDNA libraries from mouse B cell clone CH12F3-2 (which undergoes class switch recombination from IgM to IgA at an extremely high rate after activation of the cells by stimulation with cytokines), with and without stimulation with cytokines, and performing subtraction cloning using the libraries.
特許請求の範囲(英語) [claim1]
1. An isolated antibody or antigen binding portion thereof that specifically binds to a polypeptide consisting of SEQ ID NO: 8.
[claim2]
2. An isolated antibody or antigen binding portion thereof that specifically binds to: a mammalian polypeptide encoded by a nucleic acid that hybridizes to the complement of the full length of the coding sequence of SEQ ID NO:7 in 0.9% NaCl at 75 deg. C., wherein the polypeptide has a cytidine deaminase activity.
[claim3]
3. The isolated antibody or antigen binding portion thereof of claim 1, wherein the antibody is a monoclonal antibody.
[claim4]
4. The isolated antibody or antigen binding portion thereof of claim 2, wherein the antibody is a monoclonal antibody.
[claim5]
5. The isolated antibody or antigen binding portion thereof of claim 1, wherein the antibody is a humanized antibody.
[claim6]
6. The isolated antibody or antigen binding portion thereof of claim 2, wherein the antibody is a humanized antibody.
[claim7]
7. The isolated antibody or antigen binding portion thereof of claim 1, wherein the antibody inhibits the cytidine deaminase activity of the polypeptide.
[claim8]
8. The isolated antibody or antigen binding portion thereof of claim 2, wherein the antibody inhibits the cytidine deaminase activity of the polypeptide.
[claim9]
9. A composition comprising the isolated antibody or the portion thereof of claim 1, and a pharmaceutically acceptable carrier.
[claim10]
10. A composition comprising the isolated antibody or the portion thereof of claim 2, and a pharmaceutically acceptable carrier.
[claim11]
11. An isolated cell producing the antibody or antigen binding portion thereof of claim 3.
[claim12]
12. An isolated cell producing the antibody or antigen binding portion thereof of claim 4.
[claim13]
13. The cell of claim 11, wherein the cell is a hybridoma obtained by fusing a mammalian myeloma cell with said non-human mammalian B cell that produces said monoclonal antibody.
[claim14]
14. The cell of claim 12, wherein the cell is a hybridoma obtained by fusing a mammalian mycloma cell with said non-human mammalian B cell that produces said monoclonal antibody.
[claim15]
15. The cell of claim 11, wherein the cell is a transgenic cell transformed by introducing, into the cell, either or both of a nucleic acid encoding a heavy chain of the monoclonal antibody and a nucleic acid encoding a light chain of the monoclonal antibody.
[claim16]
16. The cell of claim 12, wherein the cell is a transgenic cell transformed by introducing, into the cell, either or both of a nucleic acid encoding a heavy chain of the monoclonal antibody and a nucleic acid encoding a light chain of the monoclonal antibody.
[claim17]
17. The isolated antibody or antigen binding portion thereof of claim 1, wherein the antigen binding portion thereof is selected from the group consisting of F(ab')2, Fab', Fab, variable fragment of antibody (Fv), single chain Fv (sFv), disulfide stabilized Fv (dsFv), and single domain antibody (dAb).
[claim18]
18. The isolated antibody or antigen binding portion thereof of claim 2, wherein the antigen binding portion thereof is selected from the group consisting of F(ab')2, Fab', Fab, variable fragment of antibody (Fv), single chain Fv (sFv), disulfide stabilized Fv (dsFv), and single domain antibody (dAb).
  • 発明者/出願人(英語)
  • HONJO TASUKU
  • MURAMATSU MASAMICHI
  • KYOTO UNIVERSITY
国際特許分類(IPC)
米国特許分類/主・副
  • C07K016/40
  • C12N009/78
上記の特許・技術に関心のある方は、下記「問合せ先」まで直接お問い合わせください。

PAGE TOP

close
close
close
close
close
close